報價延遲最少15分鐘:2026/04/03 09:01 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
35.31 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.14/0.56
|
|
企業價值
1.56B
|
| 資產負債 |
|
每股賬面淨值
1.41
|
| 現金流量 |
|
現金流量率
0.03
|
| 損益表 |
|
收益
272.30M
|
|
每股收益
2.77
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company partners with U.S. eyecare professionals to develop products used to manage ophthalmic conditions affecting both the front and back of the eye, such as dry eye disease, cataracts, refractive errors, glaucoma, etc. Its portfolio of branded ophthalmic pharmaceuticals includes Iheezo, Vevye, Byooviz Opuviz, Natacyn, Maxitrol, Maxidex, etc. Additionally, the company's development pipeline comprises candidates like MELT-300, H-N08, CR-01, and MELT-210, being developed to address unmet needs in eye care and selected adjacent markets. Its reportable segments are: Branded, which derives maximum revenue, and ImprimisRx. |
